A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity

PURPOSE: The primary objective of this study was to compare the cost per responder (CPR) between abatacept and adalimumab among seropositive rheumatoid arthritis (RA) patients. PATIENTS AND METHODS: CPR analysis was conducted from a US payer perspective over 24 weeks for early moderate-to-severe ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sang Hee, Han, Xue, Lobo, Francis, Nanji, Sakina, Patel, Dipen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571575/
https://www.ncbi.nlm.nih.gov/pubmed/33116698
http://dx.doi.org/10.2147/CEOR.S263903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571575/
https://www.ncbi.nlm.nih.gov/pubmed/33116698
http://dx.doi.org/10.2147/CEOR.S263903

Ejemplares similares